Cargando…
New Challenges Facing Systemic Therapies of Advanced HCC in the Era of Different First-Line Immunotherapy-Based Combinations
SIMPLE SUMMARY: In this review, we detail the data on a new treatment of hepatocellular carcinoma. A new combination of therapies, based on immunotherapy, has recently emerged as efficacious treatment. While being very interesting for patients, this raises new questions: how should we select the mos...
Autores principales: | Edeline, Julien, Meyer, Tim, Blanc, Jean-Frédéric, Raoul, Jean-Luc |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9739025/ https://www.ncbi.nlm.nih.gov/pubmed/36497349 http://dx.doi.org/10.3390/cancers14235868 |
Ejemplares similares
-
Advances in Immunotherapy for Hepatocellular Carcinoma (HCC)
por: Bicer, Fuat, et al.
Publicado: (2023) -
Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
por: Pang, Lan-Lan, et al.
Publicado: (2023) -
How to assess the efficacy or failure of targeted therapy: Deciding when to stop sorafenib in hepatocellular carcinoma
por: Raoul, Jean-Luc, et al.
Publicado: (2016) -
Immunotherapy biomarkers for HCC: contemporary challenges and emerging opportunities
por: Kwee, Sandi, et al.
Publicado: (2022) -
Sorafenib alone vs. sorafenib plus GEMOX as 1(st)-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial
por: Assenat, Eric, et al.
Publicado: (2019)